Corporate Governance
MedSci Healthcare is led by our senior management team under the direction of our Board of Directors. The Board has adopted, and periodically reviews, policies and procedures to guide it in the discharge of its oversight responsibilities.
MedSci Healthcare
Dr. Zhang was appointed as a director of the company in November 2021 and was appointed as an executive director in April 2022. He has also served as the chairman of the board of directors since November 2021. Dr. Zhang is responsible for the overall strategic development, corporate governance, and management of the group. Previously, he served as the joint general manager of Shanghai Messe Medical from November 2012 to April 2015. Since October 2009, Dr. Zhang has been serving as an associate professor at Anhui University of Chinese Medicine, and since May 2021, he has been serving as the executive director of the World Federation of Chinese Medicine Societies. Since October 2017, Dr. Zhang has also been a member of the clinical trial contract research organization branch of the China Association for Quality Management of Medical and Pharmaceutical Products. Dr. Zhang obtained his bachelor's degree in acupuncture and his master's degree in integrated Chinese and Western medicine from Anhui College of Traditional Chinese Medicine (now known as Anhui University of Chinese Medicine) in July 1999 and July 2002, respectively. He also received his Ph.D. in natural science from the University of Chinese Academy of Sciences in China in March 2006.
Executive Director and Co-CEO of the group. Mr. Fan is mainly responsible for the group's business management, with a focus on digital marketing and real-world research business lines. With over 25 years of experience in pharmaceutical marketing and sales, Mr. Fan worked at Xi'an Janssen Pharmaceutical Ltd. from January 1997 to February 2022, holding various positions, and the head of excellence business department of pulmonary hypertension and channel value before his departure. Mr. Fan obtained his Bachelor's degree in Business Administration and EMBA degree from South China University of Technology in January 2012 and June 2014, respectively.
Dr. Li has been serving as the director and general manager of Shanghai Miceutics since November 2012, and was appointed as the Co-CEO of Shanghai MedSci in March 2022. Prior to founding the group, Dr. Li served as a postdoctoral researcher at Florida State University and the University of Texas Southwestern Medical Center. Later, Dr. Li was appointed as an associate professor at Anhui University of Traditional Chinese Medicine in October 2009. Dr. Li obtained a bachelor's degree in traditional Chinese medicine and a master's degree in integrated traditional Chinese and Western medicine from Anhui University of Traditional Chinese Medicine in July 2000 and July 2003, respectively. He also received a PhD in biophysics from the University of Science and Technology of China in May 2006.
Appointed as a director of the group in November 2021, Mr. Wang was subsequently appointed as an executive director in April 2022. He also served as our Vice President since December 2021. Mr. Wang is responsible for the overall strategic planning, general management, and execution of our business operations. Since June 2016 and September 2020, he has also served as Vice President and Director of Shanghai MedSci. Mr. Wang obtained his Bachelor's degree in Clinical Medicine from China Medical University in July 2003.
MedSci Healthcare
He was appointed as our Director in November 2021 and re-designated as our non-executive Director in April 2022. Mr. Hu has been a director of Shanghai MedSci since December 2015.Mr. Hu has over 15 years of experience in investment management, strategic consulting and operations management in the biomedicine industry. He joined Qiming Venture Partners in October 2006 and is currently a managing partner of the firm.Mr. Hu has served as a director of Shanghai Sanyou Medical (SHA: 688085), APT Medical(SHA: 688617), and Amoy Diagnostics (SHE: 300685), as well as a non-executive director of Antengene Corporation (HKG: 06996) and MicroTech Medical (HKG: 2235). Mr. Hu graduated from Shanghai Medical University with a bachelor's degree in preventive medicine in July 1998. He subsequently obtained a Master's degree in Business Administration from École des Ponts Business School in France in October 2004.
Mr. Yan was appointed as our Director in November 2021 and re-designated as our non-executive Director in April 2022.
Prior to joining our Group, Mr. Yan served as a consultant at Roland Berger from December 2013 to May 2017, responsible for providing consultancy services for enterprise management. Concurrently, Mr. Yan has subsequently served as an investment associate and the investment director since June 2017 at Tencent Technology (Beijing) Co., Ltd. , a fellow subsidiary of Image Frame Investment (HK) Limited which is a shareholder of the Company, responsible for equity investment and related work.
MedSci Healthcare
Ms. Liu has been serving as an associate professor at the Antai College of Economics and Management, Shanghai Jiao Tong University since August 2001, and has also served as an independent director for Shanghai No. 1 Pharmacy (SHA: 600833), Shanghai Jielong Industry(SHA: 600836), Shanghai SafBon Water Service (SHE: 300262), Changjiang Investment Industrial(SHA: 600119), and she also served as an independent non-executive director of Glorious Property (HKG: 00845) and Shanghai Gench Education Group(HKG: 1525). The Board is of the view that Ms. Liu has the appropriate accounting or related financial management experience for the purpose of Rule 3.10(2) of the Listing Rules. Ms. Liu graduated from Shaanxi Institute of Finance), currently known as School of Economics and Finance of Xi’an Jiaotong University, in the PRC with a bachelor’s degree in finance in July 1986, and a master’s degree in economics in July 1989.
Mr. Yu was appointed as our independent non-executive Director with effect from the date of this Prospectus.He has extensive experience in branding strategy and management. Currently, Mr. Yu has served as a professor at Shanghai Jiao Tong Universitysince September 2005. Mr. Yu served as an independent director of Shandong Homey Aquatic Development(SHA:600467),, Shanghai Xujiahui Commercial (SHE:002561), Golden Home Living (SHA:603180) and Zoneco Group (SHE:002069), and he also served as an independent non-executive director of Noble Jewelry (HKG:00475) and Carpenter Tan(HKG:837). Mr. Yu received a Bachelor of Philosophy degree from Hangzhou University, China in July 1983, and a Master's degree in Management and a Doctoral degree in Management from Fudan University, China in July 1993 and July 1996, respectively.
Mr. Lau was appointed as our independent non-executive Director with effect from the date of this Prospectus. Prior to joining the Group, Mr. Lau served as the general manager at Baxter (China) Investments Co., Ltd from July 2002 to April 2009; as the president of China Biologic Products, Inc. from December 2010 to March 2012; as the chief operating officer at Eddingpharm Investment Co. Ltd. from March 2012 to February 2013; and as the chief executive officer at Amsino Medical Group from March 2013 to November 2014. Subsequently, Mr. Lau founded Shenzhen Tailai Biotechnology Co., Ltd. in July 2018 and has been the chairman of the board of directors since April 2020. Concurrently, Mr. Lau has served as an independent non-executive director of Solasia Pharma K.K.,(TYO: 4597), since December 2014; and as chairman of the board of directors and an independent director of Gland Pharma Ltd, (BOM: 543245), since June 2019. Mr. Lau obtained a bachelor’s degree in pharmaceutics from University of London in the United Kingdom.
English 
简体中文 
香港中文